The article focuses on the unique needs and considerations for cell and gene therapy (C>) manufacturing suites and how they differ from those for classic product bio-pharmaceuticals.
The article wins the 2022 Article of the Year award because the authors describe the processes and supply challenges, the GMP’s requirements, and the biosafety precautions that major companies, contract development and manufacturing organizations (CDMOs), and start-ups should consider before building multipurpose, flexible manufacturing facilities to produce successful new allogeneic and autologous treatment platforms. The article is very useful for each C> professional and stakeholder in development and manufacturing,
Chair of the Pharmaceutical Engineering Committee (PEC)
About the Award
ISPE’s Roger F. Sherwood Article of the Year award was established in 1993. Three decades later, the award showcases the best content in Pharmaceutical Engineering®, increases industry recognition, highlights ISPE’s reputation as a global knowledge leader, and bolsters magazine content quality.
Although various judges have taken part in assessing articles over the years, one constant remains: recognition of quality and excellence in content by identifying final-ists and a single winning article for each publication year.
2022 Judging
A subcommittee of the PEC served as judges for the 2022 award competition, reviewing articles and providing assessments on the following criteria: usefulness to ISPE readers; how the articles improve the knowledge of key topics; and clarity and ease of reading.
2022 Award Finalist
The other articles selected as finalists for the 2022 Roger F. Sherwood Article of the Year were:
“Introduction to Steam Quality and Testing” (July/August 2022) By Nissan Cohen, Nicholas Haycocks, Jeremy Miller, FIET, FinstR, Derek Mullins, and Keith Shuttleworth
Share Your Knowledge
Submit an article on Facilities Conversion to PE Magazine.
PE Magazine is looking for submissions focused on converting existing manufacturing plants and processes to improve efficiency and reliability, ensuring the timely delivery of quality and compliant products to patients. Topics include:
Digital innovation via automation, implementation of Pharma 4.0 principles, and artificial Intelligence
Transformation of aging facilities (brownfield versus greenfield, bluefield)
Conversion to continuous manufacturing
Adoption of single-use technology from a sustainability perspective
Facilities Conversion is the editorial theme for the July/August 2024 issue of PE magazine. Deadline for submission is 1 Mar 2024.
ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.
ISPE’s FOYA program recognizes state-of-the-art projects using innovative technologies to improve the quality of products, reduce the cost of producing high-quality medicines, and demonstrate advances in project delivery for the benefit of humanity.
ISPE has announced the establishment of the ISPE Radiopharmaceuticals Community of Practice (CoP). This initiative intends to respond to the rapid growth and unique complexities of the radiopharmaceuticals field, which is critically advancing precision medicine for conditions such as cancer.
Advanced therapy medicinal products (ATMPs) are redefining what’s possible in medicine, but their promise comes with a challenge the industry can no longer afford to postpone: how to scale manufacturing in a way that is cost-effective, resilient, and patient-ready.
